GlassScriptPhysician profile
Cory D Vergilio
NPI 1841203940
$3,587.31
in general payments reported to CMS, 2019-2025
30 companies · $475 in 2025
The $475 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $551 · 2020: $546 · 2021: $409 · 2022: $353 · 2023: $453 · 2024: $801 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,687 · Long Term Medical Supply Or Device Loan: $42.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,686.77 |
| Long Term Medical Supply Or Device Loan | $42.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $643.67 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Abbvie INC. | $538.83 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $282.71 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $263.00 | 2019-2024 | Trulance |
| Gilead Sciences, INC. | $237.25 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $193.45 | 2024 | Voquezna |
| Pfizer INC. | $188.29 | 2019-2022 | |
| Genzyme Corporation | $159.58 | 2023-2025 | |
| Lilly USA, LLC | $129.80 | 2024-2025 | Omvoh |
| Celgene Corporation | $116.86 | 2021-2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $99.00 | 2024-2025 | Iqirvo, Bylvay |
| Daiichi Sankyo INC. | $89.19 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $79.24 | 2020-2022 | |
| Qol Medical, LLC | $66.00 | 2021-2023 | Sucraid |
| Ironwood Pharmaceuticals, INC | $56.84 | 2020-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $49.79 | 2019-2020 | |
| Ethicon US, LLC | $45.13 | 2019-2021 | |
| Pentax of America, INC. | $42.38 | 2024 | Endo Stratus Co2 Insufflator |
| Ardelyx, INC. | $40.97 | 2023-2024 | Ibsrela |
| Vivus LLC | $39.62 | 2019 | |
| Romark Laboratories, Lc | $35.95 | 2020 | |
| Ferring Pharmaceuticals INC. | $32.52 | 2023-2024 | Rebyota, Cimzia |
| Regeneron Healthcare Solutions, INC. | $30.68 | 2022-2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $28.83 | 2020-2021 | |
| Sanofi Pasteur INC. | $19.62 | 2024 | |
| Fresenius Kabi USA, LLC | $17.89 | 2023 | Idacio |
| Novo Nordisk INC | $16.78 | 2025 | Wegovy |
| Amgen INC. | $15.00 | 2019 | |
| Nestle Healthcare Nutrition INC. | $14.95 | 2021 | |
| Alfasigma USA, INC. | $13.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cory Vergilio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.